Your session is about to expire
← Back to Search
Dengue Vaccine for Dengue Fever
Study Summary
This trial tests a potential new vaccine against dengue in healthy people aged 18-59; 11 visits over 7 months. Blood, urine tests & survey; optional lymph node aspiration & 12mo follow-up.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- I have received blood products within the last 4 months.My diabetes is not well controlled (A1c > 8).My asthma has been severe, needing emergency care or steroids in the last 2 years.I have a diagnosed bleeding disorder that needs special care.I have been vaccinated against dengue before.I have a form of swelling known as angioedema.I haven't taken strong immune system medications or cancer drugs in the last month.I have never been vaccinated or sick with flavivirus, nor traveled to areas where it's common.I am willing to follow specific lifestyle guidelines for the study period.I am using or will use effective birth control and have a negative pregnancy test before starting the study.My cancer is active or likely to come back during the study.I do not have a spleen or my spleen does not work properly.I am between 18 and 59 years old.I agree not to get any vaccines 28 days before or after receiving the trial vaccine.
- Group 1: Primary Heterotypic DENV Antibody Profile
- Group 2: Polytypic DENV Antibody Profile
- Group 3: Flavivirus Naive
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this experiment open to octogenarians?
"The necessary qualifications for participants of this trial are those aged between 18 and 59. For minors, there are 13 clinical trials available, while seniors can look towards 12 options."
How can individuals assess the potential risks of Flavivirus Naive?
"While there is limited data backing both safety and efficacy, due to the nature of this Phase 1 trial, our team at Power has rated Flavivirus Naive's security a score of 1."
Are there still open slots for enrollment in this experiment?
"As per the data available on clinicaltrials.gov, this particular trial is no longer accepting candidates for participation; it was initially posted to the website in late January of 2023 and saw its last update a week prior. Nevertheless, there are 26 other trials that remain open to enrollment at present time."
Is my eligibility sufficient to participate in this experiment?
"This trial is seeking two hundred individuals who have already been exposed to dengue, aged 18-59 years old. Furthermore, participants must be in good health and agree to forgo any other vaccines or travel to an endemic area throughout the study's duration. They also must commit to using a highly effective form of contraception if applicable and provide informed consent before taking part. Additionally, their absolute neutrophil count (ANC) should exceed 750 cells/microliter and creatinine levels should remain below 1.5 mg/dL."
Share this study with friends
Copy Link
Messenger